Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)

Diego F. Wyszynski, Dawn M. Waterworth, Philip J. Barter, Jonathan C Cohen, Y. Antero Kesäniemi, Robert W. Mahley, Ruth McPherson, Gérard Waeber, Thomas P. Bersot, Sanjay S. Sharma, Vikki Nolan, Lefkos T. Middleton, Scott S. Sundseth, Lindsay A. Farrer, Vincent Mooser, Scott M Grundy

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Genetic Epidemiology of Metabolic Syndrome is a multinational, family-based study to explore the genetic basis of the metabolic syndrome. Atherogenic dyslipidemia (defined as low plasma high-density lipoprotein cholesterol with elevated triglycerides (<25th and >75th percentile for age, gender, and country, respectively) identified affected subjects for the metabolic syndrome. This report examines the frequency at which atherogenic dyslipidemia predicts the metabolic syndrome of the National Cholesterol Education Program Adult Treatment Panel III (ATP-III). One thousand four hundred thirty-six (854 men/582 women) affected patients by our criteria were compared with 1,672 (737 men/935 women) unaffected persons. Affected patients had more hypertension, obesity, and hyperglycemia, and they met a higher number of ATP-III criteria (3.2 ± 1.1 SD vs 1.3 ± 1.1 SD, p <0.001). Overall, 76% of affected persons also qualified for the ATP-III definition (Cohen's κ 0.61, 95% confidence interval 0.59 to 0.64), similar to a separate group of 464 sporadic, unrelated cases (75%). Concordance increased from 41% to 82% and 88% for ages ≤35, 36 to 55, and <55 years, respectively. Affected status was also independently associated with waist circumference (p <0.001) and fasting glucose (p <0.001) but not systolic blood pressure (p = 0.43). Thus, the lipid-based criteria used to define affection status in this study substantially parallels the ATP-III definition of metabolic syndrome in subjects aged >35 years. In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors.

Original languageEnglish (US)
Pages (from-to)194-198
Number of pages5
JournalAmerican Journal of Cardiology
Volume95
Issue number2
DOIs
StatePublished - Jan 15 2005

Fingerprint

Molecular Epidemiology
Dyslipidemias
Therapeutics
Hyperglycemia
HDL Cholesterol
Triglycerides
Obesity
Cholesterol
Hypertension
Education

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). / Wyszynski, Diego F.; Waterworth, Dawn M.; Barter, Philip J.; Cohen, Jonathan C; Kesäniemi, Y. Antero; Mahley, Robert W.; McPherson, Ruth; Waeber, Gérard; Bersot, Thomas P.; Sharma, Sanjay S.; Nolan, Vikki; Middleton, Lefkos T.; Sundseth, Scott S.; Farrer, Lindsay A.; Mooser, Vincent; Grundy, Scott M.

In: American Journal of Cardiology, Vol. 95, No. 2, 15.01.2005, p. 194-198.

Research output: Contribution to journalArticle

Wyszynski, DF, Waterworth, DM, Barter, PJ, Cohen, JC, Kesäniemi, YA, Mahley, RW, McPherson, R, Waeber, G, Bersot, TP, Sharma, SS, Nolan, V, Middleton, LT, Sundseth, SS, Farrer, LA, Mooser, V & Grundy, SM 2005, 'Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)', American Journal of Cardiology, vol. 95, no. 2, pp. 194-198. https://doi.org/10.1016/j.amjcard.2004.08.091
Wyszynski, Diego F. ; Waterworth, Dawn M. ; Barter, Philip J. ; Cohen, Jonathan C ; Kesäniemi, Y. Antero ; Mahley, Robert W. ; McPherson, Ruth ; Waeber, Gérard ; Bersot, Thomas P. ; Sharma, Sanjay S. ; Nolan, Vikki ; Middleton, Lefkos T. ; Sundseth, Scott S. ; Farrer, Lindsay A. ; Mooser, Vincent ; Grundy, Scott M. / Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). In: American Journal of Cardiology. 2005 ; Vol. 95, No. 2. pp. 194-198.
@article{07f9dcc8e915437a85e137c53bef0772,
title = "Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)",
abstract = "Genetic Epidemiology of Metabolic Syndrome is a multinational, family-based study to explore the genetic basis of the metabolic syndrome. Atherogenic dyslipidemia (defined as low plasma high-density lipoprotein cholesterol with elevated triglycerides (<25th and >75th percentile for age, gender, and country, respectively) identified affected subjects for the metabolic syndrome. This report examines the frequency at which atherogenic dyslipidemia predicts the metabolic syndrome of the National Cholesterol Education Program Adult Treatment Panel III (ATP-III). One thousand four hundred thirty-six (854 men/582 women) affected patients by our criteria were compared with 1,672 (737 men/935 women) unaffected persons. Affected patients had more hypertension, obesity, and hyperglycemia, and they met a higher number of ATP-III criteria (3.2 ± 1.1 SD vs 1.3 ± 1.1 SD, p <0.001). Overall, 76{\%} of affected persons also qualified for the ATP-III definition (Cohen's κ 0.61, 95{\%} confidence interval 0.59 to 0.64), similar to a separate group of 464 sporadic, unrelated cases (75{\%}). Concordance increased from 41{\%} to 82{\%} and 88{\%} for ages ≤35, 36 to 55, and <55 years, respectively. Affected status was also independently associated with waist circumference (p <0.001) and fasting glucose (p <0.001) but not systolic blood pressure (p = 0.43). Thus, the lipid-based criteria used to define affection status in this study substantially parallels the ATP-III definition of metabolic syndrome in subjects aged >35 years. In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors.",
author = "Wyszynski, {Diego F.} and Waterworth, {Dawn M.} and Barter, {Philip J.} and Cohen, {Jonathan C} and Kes{\"a}niemi, {Y. Antero} and Mahley, {Robert W.} and Ruth McPherson and G{\'e}rard Waeber and Bersot, {Thomas P.} and Sharma, {Sanjay S.} and Vikki Nolan and Middleton, {Lefkos T.} and Sundseth, {Scott S.} and Farrer, {Lindsay A.} and Vincent Mooser and Grundy, {Scott M}",
year = "2005",
month = "1",
day = "15",
doi = "10.1016/j.amjcard.2004.08.091",
language = "English (US)",
volume = "95",
pages = "194--198",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)

AU - Wyszynski, Diego F.

AU - Waterworth, Dawn M.

AU - Barter, Philip J.

AU - Cohen, Jonathan C

AU - Kesäniemi, Y. Antero

AU - Mahley, Robert W.

AU - McPherson, Ruth

AU - Waeber, Gérard

AU - Bersot, Thomas P.

AU - Sharma, Sanjay S.

AU - Nolan, Vikki

AU - Middleton, Lefkos T.

AU - Sundseth, Scott S.

AU - Farrer, Lindsay A.

AU - Mooser, Vincent

AU - Grundy, Scott M

PY - 2005/1/15

Y1 - 2005/1/15

N2 - Genetic Epidemiology of Metabolic Syndrome is a multinational, family-based study to explore the genetic basis of the metabolic syndrome. Atherogenic dyslipidemia (defined as low plasma high-density lipoprotein cholesterol with elevated triglycerides (<25th and >75th percentile for age, gender, and country, respectively) identified affected subjects for the metabolic syndrome. This report examines the frequency at which atherogenic dyslipidemia predicts the metabolic syndrome of the National Cholesterol Education Program Adult Treatment Panel III (ATP-III). One thousand four hundred thirty-six (854 men/582 women) affected patients by our criteria were compared with 1,672 (737 men/935 women) unaffected persons. Affected patients had more hypertension, obesity, and hyperglycemia, and they met a higher number of ATP-III criteria (3.2 ± 1.1 SD vs 1.3 ± 1.1 SD, p <0.001). Overall, 76% of affected persons also qualified for the ATP-III definition (Cohen's κ 0.61, 95% confidence interval 0.59 to 0.64), similar to a separate group of 464 sporadic, unrelated cases (75%). Concordance increased from 41% to 82% and 88% for ages ≤35, 36 to 55, and <55 years, respectively. Affected status was also independently associated with waist circumference (p <0.001) and fasting glucose (p <0.001) but not systolic blood pressure (p = 0.43). Thus, the lipid-based criteria used to define affection status in this study substantially parallels the ATP-III definition of metabolic syndrome in subjects aged >35 years. In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors.

AB - Genetic Epidemiology of Metabolic Syndrome is a multinational, family-based study to explore the genetic basis of the metabolic syndrome. Atherogenic dyslipidemia (defined as low plasma high-density lipoprotein cholesterol with elevated triglycerides (<25th and >75th percentile for age, gender, and country, respectively) identified affected subjects for the metabolic syndrome. This report examines the frequency at which atherogenic dyslipidemia predicts the metabolic syndrome of the National Cholesterol Education Program Adult Treatment Panel III (ATP-III). One thousand four hundred thirty-six (854 men/582 women) affected patients by our criteria were compared with 1,672 (737 men/935 women) unaffected persons. Affected patients had more hypertension, obesity, and hyperglycemia, and they met a higher number of ATP-III criteria (3.2 ± 1.1 SD vs 1.3 ± 1.1 SD, p <0.001). Overall, 76% of affected persons also qualified for the ATP-III definition (Cohen's κ 0.61, 95% confidence interval 0.59 to 0.64), similar to a separate group of 464 sporadic, unrelated cases (75%). Concordance increased from 41% to 82% and 88% for ages ≤35, 36 to 55, and <55 years, respectively. Affected status was also independently associated with waist circumference (p <0.001) and fasting glucose (p <0.001) but not systolic blood pressure (p = 0.43). Thus, the lipid-based criteria used to define affection status in this study substantially parallels the ATP-III definition of metabolic syndrome in subjects aged >35 years. In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors.

UR - http://www.scopus.com/inward/record.url?scp=19944429029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429029&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.08.091

DO - 10.1016/j.amjcard.2004.08.091

M3 - Article

C2 - 15642551

AN - SCOPUS:19944429029

VL - 95

SP - 194

EP - 198

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 2

ER -